Biotail Medical Secures RMB 200 Million Series D Funding to Accelerate Commercialization of China's First Constraint-Type Drug-Coated Balloon
Barty Medical
Vascular Interventional and Implantable Device R&D Manufacturer
Source: Medical Device Business Review
Author: Lin Xi
Recently,Zhejiang Barty Medical Technology Co., Ltd. (BelowAbbreviation“Barty Medical”)Announced the completion of nearlyRMB 200 millionFinancing: This round of financing was led by Chuangdongfang Investment, with co-investment from Zhejiang Province’s “4+1” Biopharmaceutical and High-End Medical Device Industry Fund, Yifeng Capital, Zhongyiren Capital, and individual industry investors. Existing shareholder Junxingjian Capital continued to increase its stake, while Qifeng Capital provided financing support.Fully demonstrating the market's high recognition of the company。
(Image sourced from a screenshot of the Tianyancha app)
It is understood that,Barty MedicalEstablished in 2015, the company has been deeply engaged in the field of vascular intervention, with its product line covering two major sectors: cardiovascular intervention and peripheral vascular intervention. Over the course of more than 10 years of development, the enterprise has successivelyHonored with titles including “Little Giant” Enterprise for Specialization, Refinement, Distinctiveness, and Innovation at the national level, National High-Tech Enterprise, Zhejiang Provincial Enterprise Research Institute for High-Performance Vascular Interventional Devices, and Hangzhou Quasi-Unicorn Enterprise.
2024, the companyStar ProductsMatrixSuperPTX® Peripheral Constrained Drug-Coated BalloonBarty Medical Emerges，Become the MiddleChina’s first peripheral constrained drug-coated balloon, and also the world’s second approved third-generation vascular interventional balloon product of its kind.
TheProductFeaturing the minimally invasive treatment concept of “intervention without implantation,” this technology fills a domestic gap in China.Rapidly covered hundreds of clinical centers across China after market launch, with monthly implantation volumes continuing to rise,Has become an important clinical option in the field of interventional therapy for peripheral arterial disease.
With the recent acquisition of 200 million in financing, the company will continue to increase its investment in this productPeripheral Constraint Drug-Coated Balloonoffor purposes such as commercial promotion and the accumulation of clinical evidence, the establishment of a new generation of intelligent production bases, and the subsequent research and development of innovative vascular interventional products.
In recent years, the aging population and the number of individuals with diabetes and atherosclerosis in China have continued to expand, leading to a sustained growth in the demand for diagnosis and treatment of peripheral vascular diseases. However, traditional drug-coated balloons lack a constrained structure, making them highly prone to tearing the vascular intima during expansion, which results in a persistently high risk of post-procedural restenosis. Against this backdrop,Barty MedicalWith revolutionary technology leading peripheral balloon therapy, it has ushered in a new era of peripheral interventional balloon treatment.Barty Medical's Multiple Products and TechnologiesFilling clinical gaps,Successfully openedIntervention Without ImplantationNew incremental market in the sector,BecomeNiche SegmentofScarce incremental product categories.
Barty MedicalContinuously increasing R&D investment, achieving breakthrough progress in multiple fields such as coronary intervention and peripheral intervention, consecutivelyLaunched multiple “world’s first, China’s first domestically produced” products, achieving breakthroughs through innovative technologies that embody the principle of “offering what others do not, and excelling where others merely provide.”Highlighting its leading position and exceptional strength in the field of interventional therapy.
In 2021, the Fengtai® Flowty® excipient-free nano-needle coated coronary drug-coated balloon was approved for market launch; it is currently the only national innovative medical device product among marketed similar products featuring an excipient-free drug coating.
In 2023, the first domestically produced constrained balloon product, the Matrix Super® Peripheral Constrained Balloon, was launched, fully addressing localized clinical needs in China such as late patient presentation and long-segment vascular lesions.
In 2024, the world’s first “intervention without implantation” drug-device combination product—the coronary constrained drug-coated balloon, independently developed by Barty Medical and improved in collaboration with Academician Ge Junbo’s team at Zhongshan Hospital, for in situ lesions of large coronary vessels—was successfully launched.
With multiple innovative technologies and a robust product portfolio, the company has obtainedOver 50 ItemsCore Patents,19 sheetsNMPA Class III Medical Device Registration Certificate,8 ItemsEU CE Certification;3 ModelsProduct EntryNational Green Channel for Innovative Medical Devices。
In addition to maintaining its lead in technological innovation, Barty Medical has also implemented a comprehensive strategy for its commercialization layout:
Currently, Barty Medical’s core products have entered hundreds of clinical centers across China, with an average monthly implantation volume reaching hundreds of units and continuing to grow. Following this round of financing, the company will continue to build production facilities, expand capacity, support the steadily growing domestic surgical demand, stabilize the supply chain, and reduce reliance on foreign production lines for high-end interventional consumables.
Meanwhile, the company has intensified its overseas expansion, with products exported to more than 40 countries and regions. According to Barty Medical, two of its drug-coated balloon products are expected in the second half of the year.Coronary Flowty™, Peripheral Egyty™ObtainEU CE MDR Certification, becoming one of the first drug-coated balloon products approved globally under the new regulations and securing entry into the high-end European medical market.
Undoubtedly, leveraging its dual-growth commercialization strategy in domestic and international markets and its cutting-edge proprietary drug-coated balloon technology, Barty Medical has now secured a position in the first tier of the "implant-free intervention" track for peripheral vascular diseases both at home and abroad.
According toPublic data shows that the market size of peripheral artery balloon catheters in China and abroad in 20241.29 billion yuan, with a compound annual growth rate of up to from 2019 to 202425.16%。At the global level, the market size of peripheral interventional devices exceeded in 202527.7 billionUSD, expected to reach by 203560.8 billionUS dollars, with incremental space being released simultaneously in domestic and overseas markets.
The peripheral interventional device industry, the early market was long dominated byMedtronic, Boston Scientific, B. BraunMonopolized by leading foreign enterprises, with industry discourse power, core technologies, and market share all dominated by foreign capital.
However, as the Chinese government continues to introduce supportive policies for high-end medical devices, domestic companies represented by Barty Medical have achieved continuous breakthroughs in core technologies, significantly accelerating the pace of import substitution.In recent years, domestic alternatives have achieved substantial breakthroughs in both market share and technological innovation.
Driven by the implementation of the sixth batch of national centralized procurement for high-value medical consumables, the localization rate of peripheral drug-coated balloons in China has increased significantly from 28% in 2019 by 2025, with some authoritative market estimates indicating that their overall market share has reached67.3%around, marking the first time that domestically produced products have comprehensively surpassed foreign brands in sales/procurement volume.
Among themZhejiang Transcend Medical Co., Ltd.Leveraging the inclusion of its full range of peripheral interventional consumables in multi-provincial alliance centralized procurement, the implantation volume of its peripheral drug-coated balloons and high-pressure balloons has increased by an average of 2-3 times in markets across Beijing-Tianjin-Hebei, Jiangsu, and other regions.AcandisAll drug-coated balloons in the full above-knee and below-knee peripheral series won the bid, significantly accelerating coverage in primary hospitals;Lepu MedicalMultiple specifications of peripheral drug-coated balloons were simultaneously selected in the centralized procurement, leveraging a mature nationwide distribution network to rapidly penetrate thousands of secondary hospitals, resulting in a significant year-on-year surge in sales volume.
Riding the tailwind of centralized procurement,Chinese medical device companies are increasing their investments, expanding product pipelines and sales channels, improving commercialization strategies, and building core competitiveness.Gradually broadened the market landscape originally dominated by imported products.
Lepu MedicalLeveraging the first-mover advantage in the coronary stent sector, we have simultaneously established product lines for both coronary and peripheral drug-coated balloons. Our distribution network covers tertiary A-class, secondary, and county-level hospitals across China. Meanwhile, our overseas business extends to multiple emerging markets, including Southeast Asia and Latin America, where we are expanding international growth by capitalizing on the scaled cost advantages gained through centralized procurement.
Dingke MedicalEstablish a comprehensive portfolio of balloon catheters covering coronary, peripheral, and neurointerventional applications; independently develop differentiated innovative products such as directional scoring balloons; and simultaneously forge strategic collaborations with overseas medical device companies to leverage their mature distribution channels for the global commercialization of Chinese-developed technologies.
Undoubtedly,With a complete product matrix, both domestic and internationalCompleteBusinessLayoutleading enterprise，More capableContinuously Acquire Capital and Market Resources.Meanwhile, by focusing on addressing genuine clinical pain points with pioneering products, seizing the benefits of priority review policies for innovative medical devices, and creating differentiated, exclusive offerings, companies can secure long-term market advantages, continuously accumulate core patented technologies, and build a robust competitive moat.